140429-mrsa-superbug-petri-dish-3p_62178baa0a234dfa9412de5c491aa216.jpg
Agarplate_redbloodcells_smaller.jpg
o-MRSA-facebook.jpg
140429-mrsa-superbug-petri-dish-3p_62178baa0a234dfa9412de5c491aa216.jpg

about bkg pharma


SCROLL DOWN

about bkg pharma


BKG Pharma is a privately held Danish biopharmaceutical company exclusively committed to discovery, development and commercialization of novel antibiotics to treat multidrug-resistant infections. 

The company was founded in 2004 by CEO and inventor MD Birgit K. Giwercman who has an extensive scientific and industrial background in infectious diseases and drug development.

BKG Pharma has laboratory facilities in Copenhagen where essential in vitro research is carried out but is predominantly run as a virtual drug development company with a core team of experts overseeing the outsourcing of research and development to a large network of CROs, academics and consultants.

Chairman LL.M. Rasmus H. Schmiegelow has more than 15 years M&A, venture capital and transaction experience and has participated in more than fifty transactions on five continents. Cross-border transactional work includes licensing agreements, joint ventures and strategic alliances to facilitate international growth of large corporations and small high growth start-ups.

Agarplate_redbloodcells_smaller.jpg

bkg vet pharma


bkg vet pharma


BKG Vet Pharma is a spin-off company of BKG Pharma established in 2011 as a result of a cooperation between Danish Agriculture & Food Council and BKG Pharma.  

BKG Vet Pharma focuses specifically on applying the BKG Platform to discover and develop antibiotics against MDR infections for veterinary use.

Potential veterinary drug-candidates have shown promising toxo-kinetic results in clinical tests in target animals.   

o-MRSA-facebook.jpg

contact


contact


Questions? Send an e-mail to:

Rasmus H. Schmiegelow, chairman
rs@bkgpharma.com  

Our address:

BKG Pharma & BKG Vet Pharma
Symbion Science Park
Fruebjergvej 3
DK-2100 Copenhagen
Denmark